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Background
Control of RNA processing plays a central role in the
expression of the HIV-1 genome. From a single 9kb
transcript, more than 40 mRNAs are generated through
suboptimal splicing, a subset of which are dependent
upon the HIV-1 factor Rev for export to the cytoplasm.
To identify small molecule modulators of HIV-1 RNA
processing, we performed a screen to isolate compounds
capable of inhibiting HIV-1 gene expression post-
integration.
Materials and methods
Initial screens were performed in the HeLa rtTA
HIVΔmls cell line containing a doxycycline inducible
HIV-1 provirus. Effects of compounds on HIV-1 expres-
sion were analyzed using p24 ELISA, western blots,
in situ hybridization and qRT-PCR. To confirm that the
responses observed were not unique to this cell line,
assays were repeated in a chronically infected CD4+
T cell line (24STNLESG).
Results
Two compounds displayed significant suppression of
HIV-1 gene expression; 8-azaguanine, and 2-[2-(5-nitro-
2-thienyl)vinyl]quinoline (5350150). Both compounds
significantly reduced the production of HIV-1 Gag and
Env with limited effects on Rev and Tat accumulation.
While 8-azaguanine, was found to induce a significant
alteration in the levels of unspliced, singly spliced and
multiply spliced HIV RNAs, consistent with inducing an
oversplicing phenotype, 5350150 had a more limited
effect. Similar responses were seen using two distinct
HIV-1 infected cell lines, suggesting that the response is
conserved across multiple cell types. The lack of effect
of both compounds on Rev and Tat levels while redu-
cing expression of the HIV-1 structural proteins sug-
gested that Rev function was being affected. Consistent
with this hypothesis, both 8-azaguanine and 5350150
induced cytoplasmic accumulation of Rev suggesting an
alteration in Rev’s ability to shuttle between the nucleus
and cytoplasm and blocked nuclear export of HIV-1
genomic RNA as measured by in situ hybridization. Par-
allel analyses did not detect changes in the localization
of known shuttling host proteins (hnRNP A1, SRp20)
and only limited alterations of host RNA alternative
splicing, suggesting that HIV-1 processing is highly sen-
sitive to the effects induced by these compounds. To
validate the anti-viral activity of these compounds, their
capacity to suppress replication of HIV-1 isolates in
PBMCs is being evaluated.
Conclusions
Both 8-azaguanine and 5350150 impaired HIV-1 expres-
sion by altering viral RNA processing through effects at
the level of RNA splicing and export. Together, our
findings establish that HIV-1 RNA processing can be
modulated with small molecules to suppress HIV repli-
cation, establishing a new avenue for the treatment of
this infection.
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